Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$0 Mln
P/E Ratio
--
P/B Ratio
0
Industry P/E
--
Debt to Equity
0
ROE
-0.71 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$-31.17 Mln
EBITDA
$-39.37 Mln
Net Profit
$-36.86 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Artelo Biosciences Inc. Warrant (ARTLW)
| -85.96 | -63.87 | -70.98 | -93.78 | -74.30 | -- | -- |
|
BSE Sensex*
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
|
|---|---|
|
Artelo Biosciences Inc. Warrant (ARTLW)
| -0.25 |
|
S&P Small-Cap 600
| 13.89 |
|
BSE Sensex
| 18.74 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 1.45 | 5.24 | 0.17 | 31.62 |
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid... G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California. Read more
President, CEO, CFO, Treasurer, Secretary & Director
Mr. Gregory D. Gorgas M.B.A.
President, CEO, CFO, Treasurer, Secretary & Director
Mr. Gregory D. Gorgas M.B.A.
Headquarters
Solana Beach, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Artelo Biosciences Inc Warrant (ARTLW) stood at $ 11 Mln as on 31-Mar-24
The share price of Artelo Biosciences Inc Warrant (ARTLW) is $0.01 (NASDAQ) as of 17-Jun-2024 16:00 EDT. Artelo Biosciences Inc Warrant (ARTLW) has given a return of -74.3% in the last 3 years.
Artelo Biosciences Inc Warrant (ARTLW) has a market capitalisation of $ 0 Mln as on 17-Jun-2024. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Artelo Biosciences Inc Warrant (ARTLW) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Artelo Biosciences Inc Warrant (ARTLW) and enter the required number of quantities and click on buy to purchase the shares of Artelo Biosciences Inc Warrant (ARTLW).
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
The CEO & director of Mr. Gregory D. Gorgas M.B.A.. is Artelo Biosciences Inc Warrant (ARTLW), and CFO & Sr. VP is Mr. Gregory D. Gorgas M.B.A..
There is no promoter pledging in Artelo Biosciences Inc Warrant (ARTLW).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1
|
| Artelo Biosciences Inc. Warrant (ARTLW) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Artelo Biosciences Inc Warrant (ARTLW) was No Profit.
$0.00
(
